Evidence Gaps

PVR · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 303 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 266 participants
High

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 227 participants
Moderate

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 586 participants
Moderate